Month: November 2019

No Picture
Trading Ideas

Ford's UAW members vote to ratify new four-year contract

November 16, 2019 admin Comments Off on Ford's UAW members vote to ratify new four-year contract

The United Auto Workers union said on Friday that rank-and-file members at Ford Motor Co have voted in favor of a new four-year labor contract with the No. 2 U.S. automaker. Talks with FCA are expected to begin on Monday, a UAW spokesman said. The union said 56.3% of Ford’s hourly workers voted to approve the deal, which allowed the company to avoid a strike like the one that cost its larger rival General Motors Co about $3 billion. …read more […]

No Picture
Trading Ideas

U.S. charges another ex-JPMorgan executive with alleged market manipulation

November 16, 2019 admin Comments Off on U.S. charges another ex-JPMorgan executive with alleged market manipulation

The Department of Justice has charged another former JPMorgan Chase & Co executive with alleged racketeering and manipulating precious metals prices between 2008 and 2016, the latest in a string of similar prosecutions. The indictment against Jeffrey Ruffo, who is also charged with other federal crimes including conspiracy to commit wire fraud, is the result of an “ongoing investigation”, federal prosecutors said in a statement. Ruffo is the sixth person to be charged with alleged fraud in connection to JPMorgan’s precious metals desk. …read more […]

No Picture
Trading Ideas

UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

November 16, 2019 admin Comments Off on UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said in a statement Friday that the approval meant it had all the needed regulatory approvals and would close the acquisition on Wednesday. Amgen has agreed to buy Celgene’s Otezla business, the company said in a statement. …read more […]

No Picture
Trading Ideas

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

November 16, 2019 admin Comments Off on Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said in a statement Friday that the approval meant it had all the needed regulatory approvals and would close the acquisition on Wednesday. Amgen has agreed to buy Celgene’s Otezla business, the company said in a statement. …read more […]